■红皮银屑病(EP)是一种严重的银屑病,会影响多个器官,包括心血管系统.然而,很少有研究关注这种情况。本研究旨在评估EP患者心力衰竭的患病率和相关因素。并测量成纤维细胞生长因子23(FGF23)的血清浓度,慢性心力衰竭的潜在预测因子。
■我们回顾性研究了2005年1月至2021年10月在北京协和医院住院的EP患者。测量心力衰竭的患病率和相关因素。此外,收集17例患者的外周血样本,并与8名健康对照者的样本相匹配。用ELISA法测定血清FGF23浓度。
■我们研究了225例EP患者,男女比例为2.7:1,平均年龄为47.6±16.7岁。25名(11.1%)参与者在住院期间被诊断为心力衰竭。EP和心力衰竭患者年龄较大(58.2岁vs.46.2年,p=0.001);冠心病病史的患病率较高(32.0%vs.21.5%,p<0.001),发烧(48.0%vs.23.0%,p=0.007),感染(56.0%vs.35.5%,p=0.046);较高的hsCRP浓度(43.2mg/Lvs.8.2mg/L,p=0.005);贫血患病率较高(60.0%vs.22.0%,p<0.001),低蛋白血症(64.0%vs.42.0%,p=0.037),和高脂血症(40.0%vs.20.0%,p=0.023)比没有心力衰竭的人。EP患者的血清FGF23浓度显着高于对照组(493.1pg/mlvs.277.8pg/ml,p=0.027),治疗后显著降低(395.7pg/mlvs.463.1pg/ml,p=0.022)。
■临床医生应该意识到EP患者心力衰竭的风险,尤其是那些高龄和有冠心病史的人,严重的全身症状,高浓度的炎症生物标志物,和营养不良。
UNASSIGNED: Erythrodermic psoriasis (EP) is a severe form of psoriasis that affects multiple organs, including the cardiovascular system. However, few studies have focused on this condition.This study is aimed to assess the prevalence and factors associated with heart failure in EP patient, and to the measure the serum concentrations of fibroblast growth factor 23 (FGF23), a potential predictor of chronic heart failure.
UNASSIGNED: We retrospectively studied patients with EP hospitalized at Peking Union Medical College Hospital between January 2005 to October 2021. The prevalence of heart failure and associated factors was measured. In addition, peripheral blood samples were collected from 17 patients and matched with samples from eight healthy controls, and their serum concentrations of FGF23 were measured by ELISA.
UNASSIGNED: We studied 225 patients with EP, with a male: female ratio of 2.7:1 and a mean age of 47.6 ± 16.7 years. Twenty-five (11.1%) participants were diagnosed with heart failure during their hospital stay. The patients with EP and heart failure were older (58.2 years vs. 46.2 years, p = 0.001); had a higher prevalence of a history of coronary heart disease (32.0% vs. 21.5%, p < 0.001), fever (48.0% vs. 23.0%, p = 0.007), infection (56.0% vs. 35.5%, p = 0.046); higher hsCRP concentration (43.2 mg/L vs. 8.2 mg/L, p = 0.005); and higher prevalence of anemia (60.0% vs. 22.0%, p < 0.001), hypoalbuminemia (64.0% vs. 42.0%, p = 0.037), and hyperlipidemia (40.0% vs. 20.0%, p = 0.023) than those without heart failure. The serum FGF23 concentration was significantly higher in patients with EP than controls (493.1 pg/ml vs. 277.8 pg/ml, p = 0.027), and was significantly lower after treatment (395.7 pg/ml vs. 463.1 pg/ml, p = 0.022).
UNASSIGNED: Clinicians should be aware of the risk of heart failure in patients with EP, and especially those of advanced age and with a history of coronary heart disease, severe systemic symptoms, high concentrations of inflammatory biomarkers, and poor nutritional status.